As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line results from a phase Ib/IIa trial ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s shares closed last Friday at DKK637.20.

BMO Capital Markets cut their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd.

DHAKA, BANGLADESH – Media OutReach Newswire – 10 January 2025 – The Best Places to Work certification program has recognized Foodpanda and Novo Nordisk as the top two best places to work in ...

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...

This week, his company, announced a $50 million collaboration with the drugmaker Novo Nordisk to develop drugs for metabolic disorders, including diabetes and obesity, using data collected from ...

On Tuesday, his company, Variant Bio, based in Seattle, announced a $50 million collaboration with drugmaker Novo Nordisk to develop drugs for metabolic disorders, including diabetes and obesity ...

Danish drugmaker Novo Nordisk (NVO) (OTCPK:NONOF) and AI-focused biotech Valo Health announced Wednesday an agreement to expand their existing collaboration to discover and develop new treatments ...

Ozempic weight-loss drug maker Novo Nordisk on Wednesday expanded an existing agreement with a drug developer that uses artificial intelligence. Novo Nordisk said an agreement reached last year ...

SEATTLE, WA, USA I January 7, 2025 I Variant Bio, a genomics-driven drug discovery company, today announced a multi-year research collaboration with Novo Nordisk to discover novel targets for the ...